Home Newsfeeds Argus Research Downgrades Wolverine World Wide to Hold

Argus Research Downgrades Wolverine World Wide to Hold

Argus Research analyst John Staszak downgrades Wolverine World Wide (NYSE:WWW) from Buy to Hold.

byBenzinga Newsdesk

August 18, 2022

1 minute read

Argus Research analyst John Staszak downgrades Wolverine World Wide (NYSE:WWW) from Buy to Hold.

Accenture Analysts Cut Their Forecasts After Q4 Results

By Lisa Levin

September 29, 2:28 PM

Accenture plc (NYSE: ACN) reported mixed fourth-quarter financial results and issued weak FY24 adjusted EPS guidance.

ACN

HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Lowers Price Target to $10

By Benzinga Newsdesk

January 26, 7:12 AM

HC Wainwright & Co. analyst Vernon Bernardino maintains Aridis Pharmaceuticals (NASDAQ:ARDS) with a Buy and lowers the price target from $19 to $10.

ARDS

Gray Television Announces CFO Jim Ryan’s Upcoming Retirement After 2025 And Appointment Of Jeff Gignac To Succeed Him, Initially As Executive Vice President, Finance, On April 1, 2024, And He Will Step Into Mr. Ryan’s Role As CFO On July 1, 2024

By Happy Mohamed

February 20, 5:56 PM

Gray Television Inc. ("Gray," the "Company," "we," "us," or "our") (NYSE:GTN) announced today that Chief Financial Officer Jim Ryan has notified the

GTN

This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft

By Henry Khederian

July 1, 10:45 AM

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) creates new possibilities via medicine to cure diseases and improve people's lives, and over the past year, marked gains in investors’ portfolios.

AAPL

Argus Research Downgrades Wolverine World Wide to Hold

Related Posts

Accenture Analysts Cut Their Forecasts After Q4 Results

HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Lowers Price Target to $10

Gray Television Announces CFO Jim Ryan’s Upcoming Retirement After 2025 And Appointment Of Jeff Gignac To Succeed Him, Initially As Executive Vice President, Finance, On April 1, 2024, And He Will Step Into Mr. Ryan’s Role As CFO On July 1, 2024

This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft